好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluating the Role of Polyethylene Glycol in Improving Early Postoperative Peripheral Nerve Recovery
Neuro-rehabilitation
S17 - Neuro-rehabilitation: Expanding Therapeutic Approaches (5:18 PM-5:30 PM)
010

Evaluate whether polyethylene glycol (PEG)–mediated axonal fusion improves early sensory, motor, and patient-reported outcomes versus standard neurorrhaphy after mixed (median/ulnar) Sunderland V forearm injuries.

Upper-extremity peripheral nerve injuries (UE-PNIs) constitute the majority of traumatic PNIs (~69-73), and up to 40% of cases requiring surgery fail to restore meaningful functions. PEG is a hydrophilic fusogen that may acutely re-establish axolemmal continuity, attenuate Wallerian degeneration, and preserve neuromuscular targets, potentially accelerating recovery. This study presents preliminary results from the first randomized clinical trial evaluating PEG-mediated neurorrhaphy for mixed motor and sensory nerve injuries of the distal forearm.

Eligible participants were adults 18-75 years old presenting within 72 hours with Sunderland V UE-PNIs requiring primary repair or autograft. Blinded assessors performed Semmes-Weinstein monofilament testing (SWMT), static two-point discrimination (S2PD), Medical Research Council Classification (MRCC) sensory/motor grading, and the Michigan Hand Outcomes Questionnaire (MHQ) at approximately 1 week, 1 month, 6 months, and 12 months postoperatively. Statistical analyses used mixed-effects linear regression models. 

Thirteen patients (5 non-PEG, 8 PEG) were analyzed; demographics, injury, and operative variables were balanced. By postoperative day 21, PEG showed better sensory outcomes: lower S2PD (16.6 vs. 21.7; p = 0.008), lower SWMT (5.82 vs. 7.31; p = 0.003), and higher MRCC sensory (p = 0.02); PEG also reported lower pain (p = 0.03). Mixed-effects models across visits showed PEG associated with lower estimated S2PD (−6.68 ± 2.64; p = 0.032) and SWMT (−1.89 ± 0.63; p = 0.013), higher MRCC sensory (+1.27±0.52; p = 0.039) and motor (+1.13±0.38; p = 0.013), and higher MHQ without pain (+3.38±1.42; p = 0.046). No PEG-related adverse events or synkinesis were observed.

PEG application at neurorrhaphy sites is associated with accelerated early recovery and better patient-reported function and well-being, suggesting clinical utility in mixed distal forearm nerve reconstruction.

Authors/Disclosures
Anthony Hoang
PRESENTER
Mr. Hoang has nothing to disclose.
Barite Gutama, MD Dr. Gutama has nothing to disclose.
Ronald Cornely, MPH Mr. Cornely has nothing to disclose.
Ricardo A. Torres-Guzman, MD Dr. Torres-Guzman has nothing to disclose.
Sriya Nemani, BA Mrs. Nemani has nothing to disclose.
Yao Jun, RN Mrs. Jun has nothing to disclose.
Ling Yan, PhD Dr. Yan has nothing to disclose.
John B. Hill, MD Dr. Hill has nothing to disclose.
Shady Elmaraghi, MD Dr. Elmaraghi has nothing to disclose.
Brian Drolet Dr. Drolet has nothing to disclose.
Panambur Bhandari, MD Dr. Bhandari has nothing to disclose.
Wesley Thayer, MD, PhD Dr. Thayer has nothing to disclose.